Taipei, Taiwan, January 10, 2024 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company headquartered in Taiwan, is pleased to announce its unaudited consolidated revenues for December 2023. The company recorded NT$1,372 million in revenue, showcasing a significant 20.92% increase compared to the previous month and a 7.98% year-on-year growth.
For the fourth quarter of 2023, the unaudited consolidated revenue reached NT$3,419 million, marking a notable 7.8% increase compared to the same period in the previous year.
In December, the Asian market witnessed a remarkable 25.15% growth compared to the previous year, driven by substantial revenue increases in Taiwan and Vietnam. Additionally, Lotus achieved a significant milestone with the first shipment of Lenalidomide to Japan, underscoring the company's strategic expansion in the Japanese market. Export revenue for the month surged by 19.73%, attributed to the delivery of Buprenorphine/Naloxone to the US and the shipment of Enzalutamide and Vinorelbine to various European and Latin American markets.
Lotus Pharmaceutical's unaudited consolidated revenue for the full year of 2023 set a record high at NT$16,958 million, reflecting an impressive 16% growth compared to 2022. The Asian markets experienced a robust 22% revenue growth year-on-year, fueled by a stronger Taiwan domestic business and sustained expansion across the Southeast Asian region. Export markets also saw a 10.3% year-on-year increase, primarily due to the substantial revenue growth of Buprenorphine/Naloxone and Lenalidomide. Lotus has achieved a remarkable five consecutive years of double-digit revenue growth.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.
Media Enquiries:
Susan Liao, IR/PR Director
+886 2 2700 5908
investor@lotuspharm.com